CE-Ventures: Investment Portfolio & Startup News

Oyster Therapeutics secures a £45m Series A round from CE-Ventures to develop an oral drug for neurodegenerative diseases

Oyster Therapeutics is a pharmaceutical company developing targeted protein degraders, with an initial focus on tau-driven neurodegenerative diseases such as Alzheimer's. Its proprietary SELFTAC platform is designed to let smaller components cross biological membranes before self-assembling into bifunctional degraders.